TY  - JOUR
AU  - Hellmann, Matthew D
AU  - Paz-Ares, Luis
AU  - Bernabe Caro, Reyes
AU  - Zurawski, Bogdan
AU  - Kim, Sang-We
AU  - Carcereny Costa, Enric
AU  - Park, Keunchil
AU  - Alexandru, Aurelia
AU  - Lupinacci, Lorena
AU  - de la Mora Jimenez, Emmanuel
AU  - Sakai, Hiroshi
AU  - Albert, Istvan
AU  - Vergnenegre, Alain
AU  - Peters, Solange
AU  - Syrigos, Konstantinos
AU  - Barlesi, Fabrice
AU  - Reck, Martin
AU  - Borghaei, Hossein
AU  - Brahmer, Julie R
AU  - O'Byrne, Kenneth J
AU  - Geese, William J
AU  - Bhagavatheeswaran, Prabhu
AU  - Rabindran, Sridhar K
AU  - Kasinathan, Ravi S
AU  - Nathan, Faith E
AU  - Ramalingam, Suresh S
PY  - 2019
DO  - 10.1056/NEJMoa1910231
UR  - http://hdl.handle.net/10668/14563
T2  - The New England journal of medicine
AB  - In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents, Immunological
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - B7-H1 Antigen
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Female
KW  - Humans
KW  - Ipilimumab
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Nivolumab
KW  - Survival Analysis
TI  - Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
TY  - research article
VL  - 381
ER  -